GC Biopharma Plant Obtains WHO Pre-Qualification


South Korea facility expected to provide fill-finish capabilities.

The World Health Organization (WHO) has awarded prequalification to GC Biopharma, a biopharma company, for its fill-finish plant. Located in Ochang, South Korea, the complex is expected to produce drug products for vaccines (including sterile vials and pre-filled syringes), along with non-vaccine fill-finish and packaging. Established in 2019, the site is reportedly the largest fill-finish facility in the country.

According to the company, the new plant is equipped with an isolator facility and automation capabilities that power the entire process; it also employs a single-use system. GC Biopharma has supplied flu vaccines annually for the past three years through the Pan American Health Organization (PAHO) and the United Nations Children’s Fund (UNICEF).

“We hope [to] contribute to advancing global public health, based on our know-how and manufacturing capabilities that have produced and supplied vaccines for half a century," says EC Huh, PhD, president of GC Biopharma.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.